Genome Editing and Chimeric Antigen Receptors T Cell Therapy - Egyptian Knowledge Bank

43560

Genome Editing and Chimeric Antigen Receptors T Cell Therapy

Article

Last updated: 04 Jan 2025

Subjects

Abstract

Recent advances in genome editing technologies have significantly enhanced making specific changes in the genomes of different types cells. Genetically engineered T cells, or the 'living drugs', is considered a new era in antitumor therapy. Current clinical trials using chimeric antigen receptors (CARs) T cells showed a promising result in patients with some intractable hematological malignancies. In this Review, some of the most recent advances in CAR T cell therapy are mentioned high lightening the use of genome editing in this field.

DOI

10.21608/scumj.2017.43560

Keywords

CRISPR/Cas9, chimeric antigen receptor, T lymphocytes, gene therapy

Authors

View Authors

First Name

Ranya

Last Name

Hassan

MiddleName

Affiliation

Clinical pathology Department, Faculty of Medicine, Suez Canal university, Egypt

Email

ranyamoustafa@gmail.com

City

Orcid

Volume

Article Issue

Related Issue

6812

Issue Date

2017-10-01

Receive Date

2019-08-02

Publish Date

2017-10-01

Page Start

122

Page End

127

Print ISSN

1110-6999

Online ISSN

2090-2581

Article File

SCUMJ_Volume 20_Issue 2_Pages 122-127.pdf

PDF . 839.5kB

Link

https://scumj.journals.ekb.eg/article_43560.html

Detail API

https://scumj.journals.ekb.eg/service?article_code=43560

Order

Publication Type

Journal

Publication Title

Suez Canal University Medical Journal

Publication Link

https://scumj.journals.ekb.eg/

MainTitle